0000904454-20-000398.txt : 20200611
0000904454-20-000398.hdr.sgml : 20200611
20200611164922
ACCESSION NUMBER: 0000904454-20-000398
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200609
FILED AS OF DATE: 20200611
DATE AS OF CHANGE: 20200611
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: TREU JESSE I
CENTRAL INDEX KEY: 0001013425
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36332
FILM NUMBER: 20957707
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc.
CENTRAL INDEX KEY: 0001341235
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-761-4904
MAIL ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: Aldexa Therapeutics, Inc.
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Neuron Systems Inc
DATE OF NAME CHANGE: 20051012
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2020-06-09
0001341235
Aldeyra Therapeutics, Inc.
ALDX
0001013425
TREU JESSE I
C/O DOMAIN ASSOCIATES, LLC
202 CARNEGIE CENTER, SUITE 104
PRINCETON
NJ
08540
1
0
0
0
Stock Option (right to buy)
5.02
2020-06-09
4
A
0
26503
0
A
2021-06-09
2030-06-08
Common Stock
26503
26503
D
Stock Option (right to buy)
5.02
2020-06-09
4
A
0
2465
0
A
2021-06-09
2030-06-08
Common Stock
2465
2465
D
Stock Option (right to buy)
5.02
2020-06-09
4
A
0
2311
0
A
2021-06-09
2030-06-08
Common Stock
2311
2311
D
The option is exercisable in full on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer as a member of the Board of Directors through such vesting date.
The option is exercisable in full on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer as the chairman of the Nominating and Corporate Governance Committee of the Board of Directors through such vesting date.
The option is exercisable in full on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer as a member of the Audit Committee of the Board of Directors through such vesting date.
/s/ Lisa A. Kraeutler, Attorney-in-Fact
2020-06-11